Winship Cancer Institute - Emory University
Avatar

Integrating Immunotherapy in the Non-Surgical Management of SCCHN

By Winship Cancer Institute - Emory University FEATURING Nabil Saba
By Winship Cancer Institute - Emory University FEATURING Nabil Saba
54 views
August 31, 2022
0 Comments
Login to view comments. Click here to Login

Related Content

AUTOPLAY
13:21
NYU Langone

Management of High Risk Squamous Cell Carcinoma

Feat. M. L. Stevenson
21:20
Dana-Farber Cancer Institute

Year in Review: Updates in Non-Melanoma Skin Cancers

Feat. K. Khaddour
05:58
Insights from 2023 ESMO Annual Meeting

ESMO 2023 Insights: "Neoadjuvant Cemiplimab for Stage II to IV …

Feat. N. Gross
27:29
Total Health

2023 ASCO® Direct Philadelphia: Melanoma Updates

Feat. M. Orloff
15:39
ImmunoTherapy Bridge 2023

Neoadjuvant IO: Non-Melanoma Skin Cancer

Feat. N. Gross
24:20
Insights from 2023 ASCO® Annual Meeting

ASCO® 2023 Insights: "To Treat or Not to Treat - Challenging Sc…

Feat. K. Margolin
15:54
ImmunoTherapy Bridge 2023

Non-Melanoma Skin Cancers

Feat. P. A. Ascierto
02:41
ecancer

ESMO 2023 Insights: "Survival Results for Neoadjuvant Cemiplima…

Feat. N. Gross
18:56
Yale Cancer Center

Immunotherapy and Anti-Angiogenic Therapies in HNSCC

Feat. A. Bhatia
09:00
Winship Cancer Institute - Emory University

Harnessing IO in the Management of CSCC

Feat. N. Saba
15:09
ImmunoTherapy Bridge 2023

Best of SITC 2023 for Clinical Development and IO Trials

Feat. P. A. Ascierto
33:28
ecancer

ESMO 2022: Highlights, Commentary, and Analysis of the Key Studies

Feat. B. Gyawali
14:06
ESMO 2022 Conference Coverage

ESMO 2022 on the IT-MATTERS Study: Early Response to Leukocyte Inter…

Feat. P. Lavin
47:26
Moffitt Cancer Center

Basic and Translational Immunotherapy Approaches in Head and Neck Ca…

Feat. R. Uppaluri
05:46
ESMO 2022 Conference Coverage

ESMO 2022: NGS Helps Predict Response to IO in Recurrent/Metastatic …

Feat. O. Mirallas
21:28
UChicago Medicine

Emerging Treatment Paradigms in HNSCC

Feat. A. Rosenberg
05:19
ESMO 2022 Conference Coverage

ESMO 2022 Evaluation of the DNA Damage Response Network as a Predict…

Feat. P. Oikonomopoulou
10:41
Soo Park

Cemiplimab in Patients With Cutaneous Squamous Cell Carcinoma

06:12
ESMO 2022 Conference Coverage

ESMO 2022 on the Phase 4 KEYNOTE-B10 Study: Pembro + Carbo + Paclita…

Feat. M. Dzienis
09:06
ecancer

ESMO 2022 on the Phase 3 KEYNOTE-412 Study: Pembro With CRT vs. Plac…

Feat. J. Machiels